CAR T cell therapy - Bioray Laboratories
Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator BioRay Pharmaceutical
- Class CAR-T cell therapies; Gene therapies; Urologics
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lupus nephritis
Most Recent Events
- 14 Nov 2024 Preclinical trials in Lupus nephritis in China (Parenteral) before November 2024
- 14 Nov 2024 Bioray Laboratories plans a phase I trial for Lupus nephritis (Treatment experienced) in November 2024 (NCT06681337)